Autoimmune hemolytic anemia overview: Difference between revisions

Jump to navigation Jump to search
m (Template)
Line 15: Line 15:


==Historical Perspective==
==Historical Perspective==
The history of studies on autoimmune hemolytic anemia begins in the early 20th century with the description of clinical syndromes involving low hemoglobin in the setting of a circulating antibody. Various groups reported on the production of [[antibodies]] that could bind to red blood cells at either warm or cold temperatures. Over the years, diagnostic tests were developed and optimized to determine the exact type of antibody involved in hemolysis. Treatment modalities were developed, beginning with corticosteroids. Other immunosuppressive medications, such as rituximab, were soon found to be effective in patients with hemolytic anemia.


==Classification==
==Classification==

Revision as of 18:13, 12 April 2018

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia overview

CDC on Autoimmune hemolytic anemia overview

Autoimmune hemolytic anemia overview in the news

Blogs on Autoimmune hemolytic anemia overview

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S

Overview

Autoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia where the body's immune system attacks its own red blood cells (RBCs), leading to their destruction (hemolysis). Antibodies and associated complement system components become fixed onto the RBC surface. These antibodies can be detected with the direct antiglobulin test, also known as the direct Coombs test. AIHA can also be induced by several drugs including methyl-dopa and fluarabine.

Autoimmunity must not be confused with alloimmunity.

The terminology used in this disease is somewhat ambiguous. Although MeSH uses the term "autoimmune hemolytic anemia",[1] some sources prefer the term "immunohemolytic anemia" so drug reactions can be included in this category.[2][3]. The National Cancer Institute considers "immunohemolytic anemia", "autoimmune hemolytic anemia", and "immune complex hemolytic anemia" to all be synonyms.[4].

Overview

Historical Perspective

The history of studies on autoimmune hemolytic anemia begins in the early 20th century with the description of clinical syndromes involving low hemoglobin in the setting of a circulating antibody. Various groups reported on the production of antibodies that could bind to red blood cells at either warm or cold temperatures. Over the years, diagnostic tests were developed and optimized to determine the exact type of antibody involved in hemolysis. Treatment modalities were developed, beginning with corticosteroids. Other immunosuppressive medications, such as rituximab, were soon found to be effective in patients with hemolytic anemia.

Classification

Pathophysiology

Causes

Differentiating [Disease] from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

References

  1. Autoimmune+hemolytic+anemia at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. Wright MS (1999). "Drug-induced hemolytic anemias: increasing complications to therapeutic interventions". Clin Lab Sci. 12 (2): 115–8. PMID 10387489.
  3. Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 636. ISBN 0-7216-0187-1.
  4. "Definition of immunohemolytic anemia". NCI Dictionary of Cancer Terms. Archived from the original on 15 January 2009. Retrieved 2009-02-07.

Template:Hematology


Template:WikiDoc Sources